journavx vertex - Search News

FDA Approves 1st-in-Class Non-Opioid Pain Drug Journavx

Scientific American · 3d

What Is Journavx, the New Opioid-Free Painkiller from Vertex?

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment

Axios Vitals on MSN · 11h

FDA approves Vertex non-opioid pain drug

The FDA's approval of the non-addictive painkiller Journavx last week marked a milestone in the field of pain management. Why it matters: Millions of Americans with acute and chronic pain are prescribed opioids,

The Motley Fool on MSN · 1d

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November,

1d

Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

2d

At $31 a day, is Vertex’s new non-addictive painkiller worth the price?

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

15h

Vertex Pharmaceuticals: Strong Buy Rating Driven by Journavx Approval and Market Expansion Opportunities

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...

3d

What's Happening With VRTX Stock?

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results